726179 research-article2017

ANP0010.1177/0004867417726179ANZJP CorrespondenceANZJP Correspondence

Commentary Australian & New Zealand Journal of Psychiatry 1­–2

Commentary

Obesity dysmorphia as a psychiatric disorder: Simply fattening the DSM? Scott Griffiths1, Zoe Jenkins2 and David Castle2,3 1Melbourne

School of Psychological Sciences, The University of Melbourne, Melbourne, VIC, Australia 2St Vincent’s Hospital Melbourne, Melbourne, VIC, Australia 3Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia Corresponding author: David Castle, St Vincent’s Hospital Melbourne, PO Box 2900, Melbourne, VIC 3065, Australia. Email: [email protected] DOI: 10.1177/0004867417726179

Facts about obesity are sobering. For example, in Australia, the prevalence of obesity among adults increased from 18.5% to 27.9% between 1995 and 2015 and is projected to continue increasing (Australian Bureau of Statistics, 2015). In 2005, the annual direct cost of obesity to the Australian economy was estimated at a staggering AUD$8.3 billion (Colagiuri et  al., 2010). However, what is perhaps less widely appreciated, yet vital to informing the obesity debate, is the association of obesity with psychiatric distress and disability (Taylor et  al., 2013). This works twofold in that certain maladaptive eating patterns lead to obesity and the obesity itself becomes a source of shame and disablement. Perhaps most pertinent here is binge eating disorder (BED), granted full diagnostic status in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders

© The Royal Australian and New Zealand College of Psychiatrists 2017 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav journals.sagepub.com/home/anp

(DSM-5). BED is characterised by episodic binge eating with the sense of loss of control over eating during the binge, but without the compensatory purging and other activities that are defining features of bulimia nervosa. BED has an episodic course and can be difficult to treat, albeit certain cognitive and behavioural strategies, and medications have shown promise in randomised controlled trials (Brownley et  al., 2016). The other side of the obesity–mental illness association is the psychiatric distress and disability that are seemingly ‘secondary’ to the obesity itself; selfstigma, depression, social anxiety and associated disability are all common among people living with obesity. Of interest is that for some people with obesity, the whole problem becomes so frustrating that they seem to ‘give up’ on attempts to lose weight. For most others, the lure of magical diets and weight-loss formulations (including medications) is omnipresent and often indulged, unfortunately often without sustained weight loss. Thus, recognition of these psychosocial comorbidities – and treatment thereof – is important for trying to help people with obesity enjoy a full life. Larkin et al. (2017) have proposed ‘obesity dysmorphia’ (OD) as a new psychiatric condition, in part, to facilitate the recognition and treatment of these co-morbidities. The authors accurately state that some people with obesity experience significant body dissatisfaction and that the dietary, medical and surgical ‘cures’ they seek can be construed as maladaptive, reinforcing compulsive activities. Problems arise, however, in the

authors’ use of body dysmorphic disorder (BDD) as a blueprint for OD. A key criterion for BDD is body preoccupation, not body dissatisfaction; with the former relating to repetitive and intrusive thoughts about one’s appearance and the latter referring to negative emotional appraisals (Mitchison et  al., 2017). Furthermore, this preoccupation must be oriented towards a defect or flaw in appearance that – objectively – is either slight or non-existent. For some individuals who are obese, the subjective assessment of their body size will exceed objective appraisals, and thus, a diagnosis of BDD becomes viable. For others, the assessment of body size will be commensurate with reality. At this point, BDD is no longer a viable possibility and the resulting psychiatric distress and disability are secondary to the obesity itself. Putting aside the distinction between body dissatisfaction and preoccupation, it appears that Larkin et  al. (2017) have positioned OD as a viable diagnosis for obese individuals with congruent subjective and objective assessments of their body size. Larkin et  al. (2017) do not mention, however, that the DSM-5 already accommodates individuals who are (1) obese, (2) experience clinically significant distress and impairment around their body size/ weight and (3) report appraisals of their body size that are commensurate with reality. Specifically, individuals who report clinically distressing and/or impairing preoccupation with appearance flaws that are easily noticeable or clearly visible, as is the

Australian & New Zealand Journal of Psychiatry, 00(0)

2 case for individuals who are obese, can be diagnosed with ‘other specified obsessive-compulsive and related disorder’ (OSOCRD). The key question for Larkin et  al. (2017), is whether ‘OD’ should be demarcated from the catch-all category of OSOCRD. Furthermore, in answering this question, there must be consideration of BED, whose parent category of feeding and eating disorders is an exclusion criterion for a diagnosis of BDD. Recognition and treatment of individuals who are obese and suffer from the numerous psychosocial co-morbidities associated with obesity is both admirable and needed. However, our understanding of Larkin et al.’s (2017) proposal is that it requires a more thorough examination of whether BDD is an appropriate blueprint for their new OD disorder. Furthermore, as part of this examination, much consideration should be given to BED. In the absence of this examination, we

ANZJP Correspondence believe it is premature to expand the DSM with a new category of OD. Declaration of Conflicting Interests David Castle has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, AstraZeneca and Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Lundbeck, Janssen Cilag,Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira and Servier; and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexam­ fetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova. He has no stocks or shares in any pharmaceutical company.

Funding The authors received no financial support for the research, authorship and/or publication of this article.

Australian & New Zealand Journal of Psychiatry, 00(0)

References Australian Bureau of Statistics (2015) National health survey: 2014–2015. Federal Government of Australia. Belconnen, ACT, Australia: Australian Bureau of Statistics. Brownley KA, Berkman ND, Peat CM, et al. (2016) Binge-eating disorder in adults: A systematic review and meta-analysis. Annals of Internal Medicine 165: 409–420. Colagiuri S, Lee CMY, Colagiuri R, et al. (2010) The cost of overweight and obesity in Australia. Medical Journal of Australia 192: 260–264. Larkin D, Kirtchuk G, Yamaguchi M, et al. (2017) A proposal for the inclusion of ‘obesity dysmorphia’ in the Diagnostic and Statistical Manual of Mental Disorders. Australian & New Zealand Journal of Psychiatry. Epub ahead of print 2 August 2017. DOI: https://doi.org/ 10.1177/0004867417722641 Mitchison D, Hay P, Griffiths S, et  al. (2017) Disentangling body image: The relative associations of overvaluation, dissatisfaction, and preoccupation with psychological distress and eating disorder behaviors in male and female adolescents. The International Journal of Eating Disorders 50: 118–126. Taylor VH, Forhan M, Vigod SN, et al. (2013) The impact of obesity on quality of life. Best Practice & Research: Clinical Endocrinology & Metabolism 27: 139–146.

Obesity dysmorphia as a psychiatric disorder: Simply fattening the DSM?

Obesity dysmorphia as a psychiatric disorder: Simply fattening the DSM? - PDF Download Free
387KB Sizes 1 Downloads 8 Views

Recommend Documents


Beyond the DSM: development of a transdiagnostic psychiatric neuroscience course.
Clinical and neurobiological data suggest that psychiatric disorders, as traditionally defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), are (1) more comorbid than expected by chance, (2) often share neurobiological signatur

Epidemiology: obesity and cancer--the evidence is fattening up.
A large-scale study with 5.24 million participants has found statistically significant associations between increased BMI and 17 of 22 frequent cancers. The strongest associations were observed for cancers of the endometrium, kidney, gallbladder and

Characteristics and Psychiatric Symptoms of Internet Gaming Disorder among Adults Using Self-Reported DSM-5 Criteria.
The Section III of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) proposed nine diagnostic criteria and five cut-point criteria for Internet Gaming Disorder (IGD). We aimed to examine the efficacy of such criteria.

Is the DSM-5 chapter on somatic symptom disorder any better than DSM-IV somatoform disorder?
DSM-5 is a modest improvement on DSM-IV, notably in abandoning the distinction between medically explained and unexplained symptoms, but problems remain. The chapter text is incoherent, contradicts the classification and will be clinically unhelpful.

Poor Validity of the DSM-IV Schizoid Personality Disorder Construct as a Diagnostic Category.
This study sought to evaluate the construct validity of schizoid personality disorder (SZPD) by investigating a sample of 2,619 patients from the Norwegian Network of Personality-Focused Treatment Programs by a variety of statistical techniques. Nine

A view of obesity as a learning and memory disorder.
This articles describes how a cascade of associative relationships involving the sensory properties of foods, the nutritional consequences of their consumption, and perceived internal states may play an important role in the learned control of energy

Abdominal obesity: causal factor or simply a symptom of obesity-related health risk.
Abdominal fat (AF) reduction is advocated in the treatment of obesity-related diseases. Nonetheless, recent studies have shown additional beneficial effects against obesity-related health risks, independent of AF reduction. Therefore it is important

The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy.
After 10 years of preparation, DSM-5 was published in 2013. This paper will examine the possible effects of DSM-5 on psychiatric diagnosis and psychopharmacotherapy.